Jobs / United States / Astrazeneca Pharmaceuticals Lp
Head of Alliance and Integration Management Oncology
Astrazeneca Pharmaceuticals Lp · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Associate Director, Oncology Portfolio Analytics” (Management Analysts) in MD: $157k–$157k, median $157k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
What if your next role helped eliminate cancer as a cause of death? At AstraZeneca, our Oncology ambition is unparalleled. We’ve built and strategically acquired one of the most promising pipelines in the industry, driven by a bold vision to push the boundaries of science, change the practice of medicine, and ultimately eliminate cancer as a cause of death. You will be among inspiring oncology industry leaders who will empower you to be the best, joining teams with a shared sense of urgency to cure cancer and transform patients’ lives. The Head of Alliance and Integration Management, Oncology R&D, reports to the Vice President Head of Business Development in Oncology R&D at AstraZeneca, with accountability for global partnerships, ORD Acquisitions/Integrations and has a direct impact on the success of the Oncology R&D strategy and portfolio This is a senior strategic leadership role at the heart of AstraZeneca’s Oncology R&D ambition. The Head of Alliance and Integration Management serves as AZ’s primary representative and champion in our most consequential external partnerships, leading high-stakes negotiations, navigating complex periods of change including company acquisitions and integrations, and safeguarding AZ’s strategic interests across a global alliance portfolio. This individual drives proactive risk management and strong governance across all ORD alliances, ensuring that partnership goals remain on track and that AZ consistently demonstrates the qualities that make it a partner of choice. They will directly manage a team of Alliance Directors, provide thought leadership across the global Alliance Management community, and personally lead AZ’s most critical strategic alliances with major pharma partners. To be successful, you will need: • Strategic enterprise thinking, with the ability to understand how the goals of our partnerships contribute to AstraZeneca’s broader Oncology R&D strategy and long-term portfolio value. • Inspirational and collaborative leadership, with a proven ability to develop high-performing teams, align diverse stakeholders and drive outcomes without relying solely on formal authority. • Excellent communication skills that will clarify problems, promote teamwork, set priorities, drive toward conclusions, and keep relevant stakeholders informed. • Exceptional judgement and decisiveness, with the confidence to navigate ambiguity, anticipate risk and opportunity, and act in AZ’s best interests. • Executive-level influence and relationship-building skills, with the credibility to lead complex negotiations and build trusted relationships with senior internal and external stakeholders. • A proactive, value-focused mindset, with the ability to translate insight into action, challenge the status quo and continuously improve alliance performance and ways of working. Accountabilities: • Define and drive AZ’s alliance strategy in close collaboration with the global AM Community and BD Leadership, identifying opportunities to deepen and extend existing alliances and establish new partnerships that accelerate AstraZeneca’s long-term strategic goals. • Personally lead AZ’s most strategically significant alliances and integrations, representing AZ at the most senior levels with partner companies through complex negotiations, transitions and periods of significant organisational change, while building the relationships required to maximise long-term strategic value. • Champion the strategic health and performance of the Oncology alliance portfolio, proactively identifying emerging risks and opportunities, monitoring delivery against objectives, milestones and value-creation targets, and driving decisive course correction where required. • Equip Senior Leadership with clear, actionable portfolio